BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND ER, estrogen receptor AND Prognosis
5165 results:

  • 1. The evolvement of breast cancer therapies: What we have done and where all these head off.
    Nurlaila I; Pambudi S
    Saudi Med J; 2024 Apr; 45(4):331-340. PubMed ID: 38657992
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. H4K20me3, H3K4me2 and H3K9me2 mediate the effect of ER on prognosis in breast cancer.
    Xiao CK; Ren Y; Chen Q; Yang Y; Tang L; Xu L; Ren Z
    Epigenetics; 2024 Dec; 19(1):2343593. PubMed ID: 38643489
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Postpartum breast cancer and Survival in Women With Germline BRCA Pathogenic Variants.
    Zhang Z; Ye S; Bernhardt SM; Nelson HD; Velie EM; Borges VF; Woodward ER; Evans DGR; Schedin PJ
    JAMA Netw Open; 2024 Apr; 7(4):e247421. PubMed ID: 38639936
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Association between estrogen receptor alpha and aryl hydrocarbon receptor gene polymorphisms in the prognosis of breast cancer in Egypt.
    Aboelroos SA; Eltamany EHM; Mohamed FAM; Suliman MA
    Egypt J Immunol; 2024 Apr; 31(2):87-92. PubMed ID: 38615265
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The Vitamin D receptor as a Prognostic Marker in breast cancer-A Cohort Study.
    Huss L; Gulz-Haake I; Nilsson E; Tryggvadottir H; Nilsson L; Nodin B; Jirström K; Isaksson K; Jernström H
    Nutrients; 2024 Mar; 16(7):. PubMed ID: 38612962
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Significance of estrogen/Progesterone receptor Expression in Metaplastic breast Carcinoma.
    Hashmi AA; Mallick BA; Rashid K; Malik UA; Zia S; Zia F; Irfan M
    Dis Markers; 2024; 2024():2540356. PubMed ID: 38601434
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas.
    Okcu O; Öztürk Ç; Yalçın N; Yalçın AC; Şen B; Aydın E; Öztürk AE
    Ann Diagn Pathol; 2024 Jun; 70():152301. PubMed ID: 38581761
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study.
    Peng J; Hong Y; Chen Q; Xu F; Zhang D; Yao J; Zou Q; Yuan L; Li L; Long Q; Liao L; Liu M; Liu X; Wang S; Yi W
    Front Endocrinol (Lausanne); 2024; 15():1347762. PubMed ID: 38567311
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features.
    Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P
    J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
    Ye JH; Yu J; Huang MY; Mo YM
    Breast Cancer; 2024 May; 31(3):417-425. PubMed ID: 38561479
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [Clinicopathological characteristics and immune microenvironment of breast squamous cell carcinoma].
    Liang JY; Wang YM; Wen Z; Zhang WH; Gao ZZ; Wang Z; Guo SP
    Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):337-343. PubMed ID: 38556816
    [No Abstract]    [Full Text] [Related]  

  • 12. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
    Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Potential Value of HSP90α in prognosis of Triple-Negative breast cancer.
    Wang HF; Chen Y; Cao B; Pei J
    Med Sci Monit; 2024 Mar; 30():e943049. PubMed ID: 38553816
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
    Chi F; Griffiths JI; Nath A; Bild AH
    Breast Cancer Res; 2024 Mar; 26(1):54. PubMed ID: 38553760
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Case report: A case of Paget disease outside the axillary breast.
    Zhou Z; Zhou B; Wu X; Wei W
    Medicine (Baltimore); 2024 Mar; 103(13):e37541. PubMed ID: 38552095
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Protecting the Brain: Novel Strategies for Preventing breast cancer Brain Metastases through Selective estrogen receptor β Agonists and In Vitro Blood-Brain Barrier Models.
    Kirchner J; Völker E; Shityakov S; Saji S; Förster CY
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542355
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan.
    Esmat E; Haidary AM; Saadaat R; Rizvi SN; Aleena S; Haidari M; Hofiani SMS; Hussaini N; Hakimi A; Khairy A; Abdul-Ghafar J
    BMC Cancer; 2024 Mar; 24(1):388. PubMed ID: 38539179
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. BIRC5 expression by race, age and clinical factors in breast cancer patients.
    Hamilton AM; Walens A; Van Alsten SC; Olsson LT; Nsonwu-Farley J; Gao X; Kirk EL; Perou CM; Carey LA; Troester MA; Abdou Y
    Breast Cancer Res; 2024 Mar; 26(1):50. PubMed ID: 38515208
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms.
    Ren H; Wang Z; Zhang L; Zhu G; Li F; Chen B
    BMC Cancer; 2024 Mar; 24(1):367. PubMed ID: 38515057
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Activation of ERβ hijacks the splicing machinery to trigger R-loop formation in triple-negative breast cancer.
    Wang D; Tang M; Zhang P; Yang K; Huang L; Wu M; Shen Q; Yue J; Wang W; Gong Y; Warner M; Dai L; He H; Yang Z; Gustafsson JA; Zhou S
    Proc Natl Acad Sci U S A; 2024 Mar; 121(13):e2306814121. PubMed ID: 38513102
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 259.